After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
Reminder - Five CTS Forms will be updated on Monday September 2, 2019. Some of the forms are posted ...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...